TRENDS IN THE USE OF SECOND-GENERATION ANDROGEN RECEPTOR AXIS INHIBITORS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AND CLINICAL FACTORS PREDICTING BIOLOGICAL RECURRENCE

被引：0
|
作者：
Nakane, Keita
Watanabe, Hiromitsu
Naiki, Taku
Takahara, Kiyoshi
Yasui, Takahiro
Miyake, Hideaki
Shiroki, Ryoichi
Koie, Takuya
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP60-09
引用
收藏
页码：E1002 / E1003
页数：2
相关论文
共 50 条
  • [21] Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
    Fred Saad
    Martin Bögemann
    Kazuhiro Suzuki
    Neal Shore
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 323 - 334
  • [22] Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
    Jimenez, Natalia
    Reig, Oscar
    Marin-Aguilera, Mercedes
    Aversa, Caterina
    Ferrer-Mileo, Laura
    Font, Albert
    Rodriguez-Vida, Alejo
    Angel Climent, Miguel
    Cros, Sara
    Chirivella, Isabel
    Domenech, Montserrat
    Figols, Mariona
    Gonzalez-Billalabeitia, Enrique
    Jimenez Peralta, Daniel
    Rodriguez-Carunchio, Leonardo
    Garcia-Esteve, Samuel
    Garcia de Herreros, Marta
    Ribal, Maria J.
    Prat, Aleix
    Mellado, Begona
    CANCERS, 2022, 14 (19)
  • [23] Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
    Saad, Fred
    Boegemann, Martin
    Suzuki, Kazuhiro
    Shore, Neal
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 323 - 334
  • [24] Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
    Wenzel, Mike
    Hoeh, Benedikt
    Humke, Clara
    Cano Garcia, Cristina
    Siech, Carolin
    Steuber, Thomas
    Graefen, Markus
    Traumann, Miriam
    Kluth, Luis
    Chun, Felix K. H.
    Mandel, Philipp
    WORLD JOURNAL OF UROLOGY, 2024, 43 (01)
  • [25] Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis
    Li, Chun Xing
    Li, Cong Ying
    Wang, Yu Qiao
    Liu, Hua
    Yang, Zhan Jiang
    Zhang, Xian
    Wang, Guan Chun
    Wang, Lei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
    Chung, Doo Yong
    Ha, Jee Soo
    Cho, Kang Su
    BIOMEDICINES, 2021, 9 (06)
  • [27] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer
    Condon, Benjamin
    Liskaser, Grace
    Thangasamy, Isaac A.
    Murphy, Declan G.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 620 - 622
  • [28] Editorial Comment on "Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study"
    Arai, Seiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 321 - 322
  • [29] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
  • [30] Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium
    Uchimoto, Taizo
    Iwatsuki, Kengo
    Komura, Kazumasa
    Fukuokaya, Wataru
    Adachi, Takahiro
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Yoshizawa, Atsuhiko
    Saruta, Masanobu
    Fujimoto, Saizo
    Minami, Takafumi
    Yamamoto, Yutaka
    Yamazaki, Shogo
    Takai, Tomoaki
    Sakamoto, Moritoshi
    Nakajima, Yuki
    Nishimura, Kazuki
    Maenosono, Ryoichi
    Tsujino, Takuya
    Nakamura, Ko
    Fukushima, Tatsuo
    Nishio, Kyosuke
    Yoshikawa, Yuki
    Yamamoto, Shutaro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Mori, Keiichiro
    Yanagisawa, Takafumi
    Tsuduki, Shunsuke
    Takahara, Kiyoshi
    Inamoto, Teruo
    Fujita, Kazutoshi
    Kimura, Takahiro
    Ohno, Yoshio
    Shiroki, Ryoichi
    Azuma, Haruhito
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 123 - 133
12345